MedPath

Efficacy of tailored Helicobacter pylori eradication therapy based on susceptibility to antimicrobial agents

Not Applicable
Recruiting
Conditions
H. pylori-associated gastritis
Registration Number
JPRN-UMIN000030270
Lead Sponsor
Shiga University of Medical Science Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
310
Inclusion Criteria

Not provided

Exclusion Criteria

1. With malignant diseases 2. Negative for culture test 3. With severe liver disease 4. No informed consent 5. Not suitable by judgement of Medical Doctor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Eradication rate of tailored eradication therapy based on susceptibility to antimicrobial agents.
Secondary Outcome Measures
NameTimeMethod
1. Eradication rate of tailored tailored H. pylori eradication therapy based on susceptibility to antimicrobial agents among different CYP2C19, CYP3A4, CYP3A5 genotypes. 2.Change of abdominal symptoms between before and after eradication therapy
© Copyright 2025. All Rights Reserved by MedPath